155 related articles for article (PubMed ID: 1624676)
1. Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia.
Merola B; Colao A; Caruso E; Sarnacchiaro F; Lancranjan I; Lombardi G; Schettini G
J Endocrinol Invest; 1992 Mar; 15(3):173-6. PubMed ID: 1624676
[TBL] [Abstract][Full Text] [Related]
2. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
Merola B; Colao A; Caruso E; Sarnacchiaro F; Briganti F; Lancranjan I; Lombardi G; Schettini G
Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
[TBL] [Abstract][Full Text] [Related]
3. A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients.
Gianola D; Pedroncelli A; Montini M; Tengattini F; Pagani MD; Cortesi L; Cappi MP; Gherardi F; Lancranjan I; Pagani G
Gynecol Endocrinol; 1991 Sep; 5(3):213-6. PubMed ID: 1776507
[TBL] [Abstract][Full Text] [Related]
4. New perspectives in medical management of hyperprolactinemia.
Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Sileo F; Ferrari L; Stroppa S; Gualteroni L; Pagani G
Endocrinol Exp; 1990 Mar; 24(1-2):159-66. PubMed ID: 2361458
[TBL] [Abstract][Full Text] [Related]
5. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia.
Ciccarelli E; Ghigo E; Mazza E; Andreis M; Massara F; Lancranjan I; Camanni F
J Endocrinol Invest; 1987 Apr; 10(2):179-82. PubMed ID: 3584856
[TBL] [Abstract][Full Text] [Related]
6. Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study.
Moro M; Maraschini C; Toja P; Masala A; Alagna S; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
Horm Res; 1991; 35(3-4):137-41. PubMed ID: 1806467
[TBL] [Abstract][Full Text] [Related]
7. Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia.
Weingrill CO; Mussio W; Moraes CR; Portes E; Castro RC; Lengyel AM
Fertil Steril; 1992 Feb; 57(2):331-5. PubMed ID: 1735484
[TBL] [Abstract][Full Text] [Related]
8. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
Merola B; Sarnacchiaro F; Colao A; Di Somma C; Di Sarno A; Ferone D; Selleri A; Landi ML; Schettini G; Nappi C
Gynecol Endocrinol; 1994 Sep; 8(3):175-81. PubMed ID: 7847102
[TBL] [Abstract][Full Text] [Related]
9. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
[TBL] [Abstract][Full Text] [Related]
10. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
11. Tolerability, safety and efficacy of two formulations of Parlodel--a slow release oral form (SRO) versus registered Parlodel capsules.
Biberoğlu K; Atasü T; Shabgahi B; Kandemir O
Gynecol Obstet Invest; 1994; 37(1):6-9. PubMed ID: 8125413
[TBL] [Abstract][Full Text] [Related]
12. New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia.
Zgliczyński W; Zgliczyński S; Makowska A; Słowinska-Srzednicka J; Janik J; Jeske W; Walecki J
Endokrynol Pol; 1992; 43(3):234-41. PubMed ID: 1345564
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
Ciccarelli E; Miola C; Avataneo T; Camanni F; Besser GM; Grossman A
Fertil Steril; 1989 Dec; 52(6):930-5. PubMed ID: 2591571
[TBL] [Abstract][Full Text] [Related]
15. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
16. CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states.
Merola B; Sarnacchiaro F; Colao A; Di Somma C; Di Sarno A; Landi ML; Marzullo P; Panza N; Battista C; Lombardi G
Biomed Pharmacother; 1994; 48(3-4):167-74. PubMed ID: 7993981
[TBL] [Abstract][Full Text] [Related]
17. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
18. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
[TBL] [Abstract][Full Text] [Related]
19. Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas.
Maraschini C; Moro M; Masala A; Toja P; Alagna S; Brunani A; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
Acta Endocrinol (Copenh); 1991 Nov; 125(5):494-501. PubMed ID: 1759539
[TBL] [Abstract][Full Text] [Related]
20. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
